Oxford's summary of the presentation states that OBT076 (NCT04064359) (2-5 cycles) in combination with a checkpoint inhibitor (CPI) (1-2 cycles) showed near complete responses in low programmed cell death ligand 1 refractory solid tumor patients. Patients treated with the combination also showed tumor shrinkage, immune response, and a decrease of metastasis. The combination synergizes through a potentially novel mechanism: drug-induced depletion of CD205+ immuno-suppressive cells and subsequent T-cell activation.

Based on this preliminary data, Oxford will advance OBT076 into single agent and combination trials (with CPIs) in both checkpoint-naïve and resistant patients, according to the summary.

Kite, Oxford BioTherapeutics partner on novel oncology targets
Kite, a Gilead company, and Oxford BioTherapeutics have entered into a research collaboration to evaluate five novel cell therapy targets for hematologic...

Boehringer Ingelheim, Oxford BioTherapeutics partner further on antibodies
Boehringer Ingelheim and Oxford BioTherapeutics are partnering to discover novel targets for cancer immunotherapies using the Oxford Genome Anatomy Project's...